Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop

Paul G. Kluetz, Bindu Kanapuru, Steven Lemery, Laura Lee Johnson, Mallorie H. Fiero, Karen Arscott, Yolanda Barbachano, Ethan Basch, Michelle Campbell, Joseph C. Cappelleri, David Cella, Charles Cleeland, Corneel Coens, Selena Daniels, Crystal S. Denlinger, Dianne L. Fairclough, James R. Hillard, Lori Minasian, Sandra A. Mitchell, Daniel O'ConnorSheetal Patel, Eric H. Rubin, Anna Ryden, Katherine Soltys, Rajeshwari Sridhara, Gita Thanarajasingam, Galina Velikova, Stephen Joel Coons

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The US Food and Drug Administration and the Critical Path Institute's Patient-Reported Outcome (PRO) Consortium convened a cosponsored workshop on the use of PRO measures to inform the assessment of safety and tolerability in cancer clinical trials. A broad array of international stakeholders involved in oncology drug development and PRO measurement science provided perspectives on the role of PRO measures to provide complementary clinical data on the symptomatic side effects of anticancer agents. Speakers and panelists explored the utility of information derived from existing and emerging PRO measures, focusing on the PRO version of the National Cancer Institute's Common Terminology Criteria for Adverse Events. Panelists and speakers discussed potential ways to improve the collection, analysis, and presentation of PRO data describing symptomatic adverse events to support drug development and better inform regulatory and treatment decisions. Workshop participants concluded the day with a discussion of possible approaches to the patient-reported assessment of an investigational drug's overall side effect burden as a potential clinical trial end point. The Food and Drug Administration reiterated its commitment to collaborate with international drug development stakeholders to identify rigorous methods to incorporate the patient perspective into the development of cancer therapeutics.

Original languageEnglish (US)
Pages (from-to)742-747
Number of pages6
JournalValue in Health
Volume21
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Critical Pathways
Education
Neoplasms
United States Food and Drug Administration
Therapeutics
Clinical Trials
Pharmaceutical Preparations
Investigational Drugs
National Cancer Institute (U.S.)
Patient Reported Outcome Measures
Drug-Related Side Effects and Adverse Reactions
Terminology
Antineoplastic Agents
Safety

Keywords

  • drug safety
  • oncology
  • patient-reported outcomes
  • PRO-CTCAE
  • tolerability

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures : Summary of an FDA and Critical Path Institute Workshop. / Kluetz, Paul G.; Kanapuru, Bindu; Lemery, Steven; Johnson, Laura Lee; Fiero, Mallorie H.; Arscott, Karen; Barbachano, Yolanda; Basch, Ethan; Campbell, Michelle; Cappelleri, Joseph C.; Cella, David; Cleeland, Charles; Coens, Corneel; Daniels, Selena; Denlinger, Crystal S.; Fairclough, Dianne L.; Hillard, James R.; Minasian, Lori; Mitchell, Sandra A.; O'Connor, Daniel; Patel, Sheetal; Rubin, Eric H.; Ryden, Anna; Soltys, Katherine; Sridhara, Rajeshwari; Thanarajasingam, Gita; Velikova, Galina; Coons, Stephen Joel.

In: Value in Health, Vol. 21, No. 6, 01.06.2018, p. 742-747.

Research output: Contribution to journalArticle

Kluetz, PG, Kanapuru, B, Lemery, S, Johnson, LL, Fiero, MH, Arscott, K, Barbachano, Y, Basch, E, Campbell, M, Cappelleri, JC, Cella, D, Cleeland, C, Coens, C, Daniels, S, Denlinger, CS, Fairclough, DL, Hillard, JR, Minasian, L, Mitchell, SA, O'Connor, D, Patel, S, Rubin, EH, Ryden, A, Soltys, K, Sridhara, R, Thanarajasingam, G, Velikova, G & Coons, SJ 2018, 'Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop', Value in Health, vol. 21, no. 6, pp. 742-747. https://doi.org/10.1016/j.jval.2017.09.009
Kluetz, Paul G. ; Kanapuru, Bindu ; Lemery, Steven ; Johnson, Laura Lee ; Fiero, Mallorie H. ; Arscott, Karen ; Barbachano, Yolanda ; Basch, Ethan ; Campbell, Michelle ; Cappelleri, Joseph C. ; Cella, David ; Cleeland, Charles ; Coens, Corneel ; Daniels, Selena ; Denlinger, Crystal S. ; Fairclough, Dianne L. ; Hillard, James R. ; Minasian, Lori ; Mitchell, Sandra A. ; O'Connor, Daniel ; Patel, Sheetal ; Rubin, Eric H. ; Ryden, Anna ; Soltys, Katherine ; Sridhara, Rajeshwari ; Thanarajasingam, Gita ; Velikova, Galina ; Coons, Stephen Joel. / Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures : Summary of an FDA and Critical Path Institute Workshop. In: Value in Health. 2018 ; Vol. 21, No. 6. pp. 742-747.
@article{e5ed420a662d4d1bb32e335ad7cf59f1,
title = "Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop",
abstract = "The US Food and Drug Administration and the Critical Path Institute's Patient-Reported Outcome (PRO) Consortium convened a cosponsored workshop on the use of PRO measures to inform the assessment of safety and tolerability in cancer clinical trials. A broad array of international stakeholders involved in oncology drug development and PRO measurement science provided perspectives on the role of PRO measures to provide complementary clinical data on the symptomatic side effects of anticancer agents. Speakers and panelists explored the utility of information derived from existing and emerging PRO measures, focusing on the PRO version of the National Cancer Institute's Common Terminology Criteria for Adverse Events. Panelists and speakers discussed potential ways to improve the collection, analysis, and presentation of PRO data describing symptomatic adverse events to support drug development and better inform regulatory and treatment decisions. Workshop participants concluded the day with a discussion of possible approaches to the patient-reported assessment of an investigational drug's overall side effect burden as a potential clinical trial end point. The Food and Drug Administration reiterated its commitment to collaborate with international drug development stakeholders to identify rigorous methods to incorporate the patient perspective into the development of cancer therapeutics.",
keywords = "drug safety, oncology, patient-reported outcomes, PRO-CTCAE, tolerability",
author = "Kluetz, {Paul G.} and Bindu Kanapuru and Steven Lemery and Johnson, {Laura Lee} and Fiero, {Mallorie H.} and Karen Arscott and Yolanda Barbachano and Ethan Basch and Michelle Campbell and Cappelleri, {Joseph C.} and David Cella and Charles Cleeland and Corneel Coens and Selena Daniels and Denlinger, {Crystal S.} and Fairclough, {Dianne L.} and Hillard, {James R.} and Lori Minasian and Mitchell, {Sandra A.} and Daniel O'Connor and Sheetal Patel and Rubin, {Eric H.} and Anna Ryden and Katherine Soltys and Rajeshwari Sridhara and Gita Thanarajasingam and Galina Velikova and Coons, {Stephen Joel}",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.jval.2017.09.009",
language = "English (US)",
volume = "21",
pages = "742--747",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures

T2 - Summary of an FDA and Critical Path Institute Workshop

AU - Kluetz, Paul G.

AU - Kanapuru, Bindu

AU - Lemery, Steven

AU - Johnson, Laura Lee

AU - Fiero, Mallorie H.

AU - Arscott, Karen

AU - Barbachano, Yolanda

AU - Basch, Ethan

AU - Campbell, Michelle

AU - Cappelleri, Joseph C.

AU - Cella, David

AU - Cleeland, Charles

AU - Coens, Corneel

AU - Daniels, Selena

AU - Denlinger, Crystal S.

AU - Fairclough, Dianne L.

AU - Hillard, James R.

AU - Minasian, Lori

AU - Mitchell, Sandra A.

AU - O'Connor, Daniel

AU - Patel, Sheetal

AU - Rubin, Eric H.

AU - Ryden, Anna

AU - Soltys, Katherine

AU - Sridhara, Rajeshwari

AU - Thanarajasingam, Gita

AU - Velikova, Galina

AU - Coons, Stephen Joel

PY - 2018/6/1

Y1 - 2018/6/1

N2 - The US Food and Drug Administration and the Critical Path Institute's Patient-Reported Outcome (PRO) Consortium convened a cosponsored workshop on the use of PRO measures to inform the assessment of safety and tolerability in cancer clinical trials. A broad array of international stakeholders involved in oncology drug development and PRO measurement science provided perspectives on the role of PRO measures to provide complementary clinical data on the symptomatic side effects of anticancer agents. Speakers and panelists explored the utility of information derived from existing and emerging PRO measures, focusing on the PRO version of the National Cancer Institute's Common Terminology Criteria for Adverse Events. Panelists and speakers discussed potential ways to improve the collection, analysis, and presentation of PRO data describing symptomatic adverse events to support drug development and better inform regulatory and treatment decisions. Workshop participants concluded the day with a discussion of possible approaches to the patient-reported assessment of an investigational drug's overall side effect burden as a potential clinical trial end point. The Food and Drug Administration reiterated its commitment to collaborate with international drug development stakeholders to identify rigorous methods to incorporate the patient perspective into the development of cancer therapeutics.

AB - The US Food and Drug Administration and the Critical Path Institute's Patient-Reported Outcome (PRO) Consortium convened a cosponsored workshop on the use of PRO measures to inform the assessment of safety and tolerability in cancer clinical trials. A broad array of international stakeholders involved in oncology drug development and PRO measurement science provided perspectives on the role of PRO measures to provide complementary clinical data on the symptomatic side effects of anticancer agents. Speakers and panelists explored the utility of information derived from existing and emerging PRO measures, focusing on the PRO version of the National Cancer Institute's Common Terminology Criteria for Adverse Events. Panelists and speakers discussed potential ways to improve the collection, analysis, and presentation of PRO data describing symptomatic adverse events to support drug development and better inform regulatory and treatment decisions. Workshop participants concluded the day with a discussion of possible approaches to the patient-reported assessment of an investigational drug's overall side effect burden as a potential clinical trial end point. The Food and Drug Administration reiterated its commitment to collaborate with international drug development stakeholders to identify rigorous methods to incorporate the patient perspective into the development of cancer therapeutics.

KW - drug safety

KW - oncology

KW - patient-reported outcomes

KW - PRO-CTCAE

KW - tolerability

UR - http://www.scopus.com/inward/record.url?scp=85032979409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032979409&partnerID=8YFLogxK

U2 - 10.1016/j.jval.2017.09.009

DO - 10.1016/j.jval.2017.09.009

M3 - Article

C2 - 29909880

AN - SCOPUS:85032979409

VL - 21

SP - 742

EP - 747

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 6

ER -